News

Study findings suggest maintenance therapy is becoming more common following second-line or third-line platinum-based chemotherapy in patients with platinum-sensitive recurrent ovarian cancer.

Study findings suggest durvalumab plus chemotherapy is not a cost-effective first-line treatment option for patients with extensive-stage SCLC.

Findings from a recent study suggest that compliance with the National Quality Forum’s measure 1822 have increased over time among patients treated for metastatic non–small cell lung cancer.

A recent article detailing a cyberattack on the University of Vermont Health Network discusses the impact the attack had on cancer care delivery and offers advice on oncology practices that can be implemented to lessen the impact of a...

Early progression after first-line TKIs for metastatic RCC is associated with worse outcomes and higher healthcare resource utilization and costs than delayed progression.

Pembrolizumab is cost-effective for the treatment of BRAF-mutant stage III melanoma, but dabrafenib-trametinib is not, according to study findings.

Study findings suggest that breast cancer outcomes can improve if steps are taken to increase the uptake of screening mammography.

An expert panel developed standards and guidance for oncology clinicians who are utilizing telehealth for their patients.

Findings from a recent study suggest strategies for oncology clinicians to reduce the stigmatizing association of palliative care with end of life.

Findings from recent study indicate olaparib is more cost-effective than niraparib for maintenance therapy in patients with recurrent platinum-sensitive ovarian cancer.